The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy.
Mogensen CE, Christensen CK, Vittinghus E.
Diabetes. 1983 May;32 Suppl 2:64-78. doi: 10.2337/diab.32.2.s64.
Diabetic nephropathy.
Ritz E.
Saudi J Kidney Dis Transpl. 2006 Dec;17(4):481-90.
The effects of dual and triple combinations of trandolapril, telmisartan, and verapamil on overt proteinuria in the patients with diabetic nephropathy.
Albayrak B, Cankaya E, Cetinkaya R, Cerrah S, Bilen Y.
Saudi J Kidney Dis Transpl. 2016 May;27(3):512-8. doi: 10.4103/1319-2442.182385.
Diabetic nephropathy.
Ibrahim HA, Vora JP.
Baillieres Best Pract Res Clin Endocrinol Metab. 1999 Jul;13(2):239-64. doi: 10.1053/beem.1999.0018.
Curcumin as a major active component of turmeric attenuates proteinuria in patients with overt diabetic nephropathy.
Vanaie A, Shahidi S, Iraj B, Siadat ZD, Kabirzade M, Shakiba F, Mohammadi M, Parvizian H.
J Res Med Sci. 2019 Aug 28;24:77. doi: 10.4103/jrms.JRMS_1055_18. eCollection 2019.
Clinical practice: proteinuria.
Ariceta G.
Eur J Pediatr. 2011 Jan;170(1):15-20. doi: 10.1007/s00431-010-1334-0. Epub 2010 Nov 10.
Pathogenesis of diabetic nephropathy.
Raptis AE, Viberti G.
Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:S424-37. doi: 10.1055/s-2001-18600.
Losartan in diabetic nephropathy.
Perico N, Ruggenenti P, Remuzzi G.
Expert Rev Cardiovasc Ther. 2004 Jul;2(4):473-83. doi: 10.1586/14779072.2.4.473.
Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice.
Tahara A, Takasu T.
Naunyn Schmiedebergs Arch Pharmacol. 2018 Apr;391(4):395-406. doi: 10.1007/s00210-018-1469-5. Epub 2018 Jan 26.
Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy.
Wu CC, Chen JS, Lu KC, Chen CC, Lin SH, Chu P, Sytwu HK, Lin YF.
Clin Chim Acta. 2010 May 2;411(9-10):700-4. doi: 10.1016/j.cca.2010.01.036. Epub 2010 Feb 4.
